Oncology

Recent analysis supports the potential importance of using biosimiliars of granulocyte colony stimulating factor to manage neutropenia affecting post-chemotherapy and post-op patients.

Dermatologists have conducted a research study that proves "smartphone microscopes" can improve the detection of skin cancer in remote areas and in developing nations, where specialists are not as easily accessible to patients.

FDA has granted a Priority Review designation for the breakthrough programmed death ligand-1 inhibitor atezolizumab, for the treatment of bladder cancer.

Updated guidelines on the use of colony-stimulating factors (CSFs) in people with cancer address the strengths and limitations of the use of CSFs, which reduce the risk of neutropenia.

Idelalisib has presented serious adverse events in combination trials in both the US and Europe.

At the end of February, Ted Okon, MBA, executive director of the Community Oncology Alliance (COA), answered questions on Twitter about the latest trends in cancer care and discussed COA’s concerns with the president’s moonshot initiative and the 340B drug pricing program.

A new report published by the American Society of Clinical Oncology has drawn a mixed picture of oncology care in the United States-reduced mortality, increased survivors, and progress in treatment coupled with unsustainable costs and an unstable clinical setting.

Two inhibitors of the vascular endothelial growth factor receptor approved for the treatment of metastatic renal cell cancer do not prevent cancer recurrence when used in the adjuvant setting following surgery, according to a new study in the Lancet.

According to the American Society of Clinical Oncology, TAPUR provides patients access to drugs at no cost, and is designed to evaluate FDA-approved targeted agents for indications other than those on the drug’s label.

Increased medical provider consolidation with hospitals and/or health systems results in increased spending on outpatient prescription drug-based cancer treatment.

The proposals recommend modernizing policies across the healthcare industry, including the drug discovery and development process, promoting value-driven healthcare, increasing the consumer voice, and addressing market distortions.

Be The First is a 5-year, $50 million initiative to help deliver the nation's first tobacco-free generation.

Several healthcare organizations have sent a letter to HHS urging withdrawal of this reimbursement model.

The report found higher death rates from liver cancer among the age group most at risk for hepatitis C virus, those born between 1945 and 1965. But increased rates of diabetes, obesity, and alcohol use are to blame for rising liver cancer deaths as well.

A study conducted in Denmark identified an inverse association between controlling diabetes, through diet or oral medications, and breast density.

CMS has announced its plans to evaluate a new value-based payment model for prescription drugs covered under the Part B program. This is yet another move by the federal body to ensure quality care for Medicare enrollees.

Based on their survey results, the authors conclude that clinician communication following detection of pulmonary nodules can help bridge knowledge gaps and relieve stress.

21st Century Oncology has informed patients that their patient database was compromised late last year.

Results of the study in JAMA underscore the importance of advance care planning.

Senators Amy Klobuchar (D-MN) and Jeanne Shaheen (D-NH) have sent a letter to the FDA urging the regulatory body to find efficient ways to distribute expensive cancer drugs.

Panelists discussing quality metrics in oncology were not sure payment and federal policies could keep pace with what's happening on the front lines.

CMS has attempted to tailor ACOs to meet a variety of needs and levels of risk, depending on where parties are in their knowledge level of payment reform.

By monitoring for mutations in the circulating tumor DNA of melanoma patients undergoing treatment, researchers at Cancer Research UK Manchester Institute are confident they can predict how patients will respond to their treatment and whether their disease would relapse.

Yousuf Zafar, MD, MHS, found that most cancer patients would like to discuss financial concerns with their doctors, but few actually do, for a variety of reasons.